Aurinia Pharmaceuticals (AUPH) Projected to Post Quarterly Earnings on Thursday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) is expected to be announcing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Aurinia Pharmaceuticals to post earnings of $0.21 per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:30 AM ET.

Aurinia Pharmaceuticals Price Performance

Shares of AUPH opened at $14.31 on Thursday. The company has a quick ratio of 5.17, a current ratio of 5.76 and a debt-to-equity ratio of 0.15. The stock has a market cap of $1.89 billion, a PE ratio of 25.55 and a beta of 1.50. Aurinia Pharmaceuticals has a 12-month low of $6.55 and a 12-month high of $16.54. The business has a 50-day simple moving average of $15.17 and a two-hundred day simple moving average of $13.78.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on AUPH. Jefferies Financial Group raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the company from $10.00 to $21.00 in a research note on Friday, November 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, January 21st. Royal Bank Of Canada restated a “sector perform” rating and issued a $15.00 price target (up from $9.00) on shares of Aurinia Pharmaceuticals in a research report on Wednesday, November 5th. Leerink Partners lowered shares of Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and lifted their price target for the stock from $15.00 to $16.00 in a report on Wednesday, December 3rd. Finally, Bloom Burton cut shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Two equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Aurinia Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $17.25.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of AUPH. MML Investors Services LLC grew its holdings in Aurinia Pharmaceuticals by 12.7% during the 4th quarter. MML Investors Services LLC now owns 15,643 shares of the biotechnology company’s stock worth $250,000 after acquiring an additional 1,765 shares during the period. Wellington Management Group LLP grew its stake in Aurinia Pharmaceuticals by 4.7% during the fourth quarter. Wellington Management Group LLP now owns 53,721 shares of the biotechnology company’s stock worth $857,000 after purchasing an additional 2,421 shares during the period. BNP Paribas Financial Markets increased its holdings in Aurinia Pharmaceuticals by 32.4% in the second quarter. BNP Paribas Financial Markets now owns 13,034 shares of the biotechnology company’s stock worth $110,000 after purchasing an additional 3,191 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Aurinia Pharmaceuticals by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company’s stock worth $642,000 after purchasing an additional 3,497 shares in the last quarter. Finally, Creative Planning lifted its stake in Aurinia Pharmaceuticals by 21.0% in the second quarter. Creative Planning now owns 20,699 shares of the biotechnology company’s stock valued at $175,000 after buying an additional 3,594 shares during the period. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.